Chuaning Biotech: Net profit of 769 million yuan in 2025, will explore the practical application of intelligent computers in production capacity with partners.

LightningPacketLoss · 2026-03-31T14:38:32+00:00

Chuanning Biotechnology releases 2025 annual report, with revenue of 4.61 billion yuan, down 19.8% year-on-year; net profit of 76.09 million yuan, down 45.08% year-on-year. The company has established a partnership with Shanghai Jincheng Technology to promote intelligent computer-assisted biological research and development. By increasing experimental tanks and dynamic regulation technology, the company aims to improve the yield of thiocyanate erythromycin.

LightningPacketLoss

2026-03-31 14:38:32

Abstract generation in progress

On March 30, Chuan Ning Bio announced its 2025 annual report. The company reported operating revenue of RMB 4.61 billion, down 19.8% year over year; among them, thio-succinyl erythromycin achieved a main business revenue share of 38.4%. Within the categories, cephalosporin intermediates accounted for 22.4% of main business revenue, penicillin intermediates accounted for 37.44% of main business revenue, and other products accounted for 1.79% of main business revenue. Net profit attributable to owners of the parent company was RMB 769.009 million, down 45.08% year over year; the company’s basic earnings per share were RMB 0.34, down 46.03% year over year.

The announcement mentioned that during the reporting period, the company established a strategic partnership with Shanghai JinQing Technology. Both sides will collaborate in areas such as enabling the fermentation industry through computer data processing technologies, research and development of intelligent computer-aided synthetic biology, and joint development of new products.

As of the date when the annual report was disclosed, the company had already added experimental tanks to its thio-succinyl erythromycin production lines, and successfully achieved smart computer virtual engineers’ dynamic control on the experimental tanks. This enables dynamic parameter control during complex biological fermentation and real-time generation of the optimal fermentation方案, thereby improving the thio-succinyl erythromycin fermentation output of the experimental tanks.

(Chuan Ning Bio announcement)

(Editor: Yang Yan, Lin Chen)

Keywords:

                                                            Medical

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes